Clinical trials: Active Population
Depressive Disorder
A Study Of New Medicine (GSK 372475) For The Treatment Of Depression
To evaluate the efficacy, safety, and tolerability of GSK372475 compared with placebo in the treatment of outpatient subjects with Major Depressive Disorder (MDD)
- Trial name
- NCT00448058
- Testing
- GSK372475, venlafaxine
- Where
- 42 sites in Australia, Belgium and 10 more
- Volunteers
- 396 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
AZD7268 Safety and Tolerability Study
The purpose of this study is to prove the principle that treatment with AZD7268 reduces depressive symptoms in patients with Major Depressive Disorder (MDD) compared with placebo.
- Trial name
- NCT01020799
- Testing
- AZD7268, Escitalopram
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan
The purpose of this study is to evaluate the Efficacy and Safety of Fimasartan in patients with hypertensive diabetic chronic kidney disease.
- Trial name
- NCT02620306
- Testing
- Fimsartan 60mg~120mg, Losartan 50mg~100mg
- Where
- South Korea
- Volunteers
- 351 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Perennial Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.
- Trial name
- NCT01133626
- Testing
- Prednisone capsules, Beclomethasone dipropionate
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tinea Pedis
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with…
- Trial name
- NCT01580878
- Testing
- Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle
- Volunteers
- 707 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Type 2 DM Patients With Moderate or Severe Renal Impairment
A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)
Therapuetic options are limited for Type 2 Diabetes Mellitus (T2DM) pateints with renal impairment. This clinical study is to asses safety and efficacy of the DPP-4 inhibitor gemigliptin in patients with type 2 DM and moderate or…
- Trial name
- GUARD (NCT01968044)
- Testing
- Gemigliptin
- Where
- South Korea
- Volunteers
- 132 people
- Sponsor
- LG Life Sciences
Ulcerative Colitis
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis
This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis.
- Trial name
- NCT00073021
- Testing
- Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
- Where
- 57 sites in United States, Canada and 1 more
- Volunteers
- 386 people
- Sponsor
- Warner Chilcott
Periodontal Diseases
Standard Root Planing vs. Periodontal Structure Repair Device for Treatment of Pockets Caused by Periodontal Disease
This study evaluates the efficacy and safety of Periodontal Structure Repair device (PSR) compared to conventional periodontal therapy (scaling and root planing) for the treatment of periodontal pockets caused by periodontal…
- Trial name
- NCT03671512
- Testing
- Periodontal Structure Repair (PSR), Standard Root Planing
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Periovance, Inc
Type 2 Diabetes
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes…
- Trial name
- NCT07082114
- Testing
- HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Pharyngitis
Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis
The purpose of this trial is to investigate efficacy and tolerability of lozenges containing 20 mg a mbroxol hydrochloride (Mucoangin?) relative to lozenges containing placebo and lozenges containing 3 mg benzocaine in relieving…
- Trial name
- NCT00148499
- Testing
- Ambroxol hydrochloride (Mucoangin?), benzocaine
- Where
- 14 sites in Romania, Ukraine
- Volunteers
- 751 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
This study employs a multicenter, randomized, double-blind, placebo-controlled, parallel-group, continuous treatment design to evaluate the efficacy, safety, PPK characteristics, and PD effects of H021 Enteric-coated Tablets…
- Trial name
- NCT07677514
- Testing
- H021 Enteric-coated Tablets Low-dose Group, H021 Enteric-coated Tablets High-dose Group
- Where
- 24 sites in United States, China
- Volunteers
- 156 people
- Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
Reflux Esophagitis
The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient…
- Trial name
- X842 (NCT07079540)
- Testing
- X842, Lansoprazole
- Where
- 53 sites in China
- Volunteers
- 380 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Ocular Hypertension, Open Angle-glaucoma
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation…
- Trial name
- NCT02083289
- Testing
- ONO-9054, Latanoprost
- Where
- 12 sites in United States
- Volunteers
- 123 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Heart Failure (HF)
A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
To assess the efficacy of 30 mg of BAY1753011, with or without furosemide, versus furosemide alone in patients with heart failure and objective evidence of congestion.
- Trial name
- AVANTI (NCT03901729)
- Testing
- BAY 1753011, Furosemide
- Where
- 66 sites in Austria, Bulgaria and 7 more
- Volunteers
- 482 people
- Sponsor
- Bayer
Polycythemia Vera
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone.
- Trial name
- NCT07722611
- Testing
- Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
- Where
- 2 sites in United States, Israel
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Acne Vulgaris
Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris
The objective of this study is to evaluate the therapeutic equivalence and safety of Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel (Taro Pharmaceuticals Inc.) and Epiduo® (Adapalene and Benzoyl Peroxide 0.1%/2.5% Gel) (Galderma…
- Trial name
- NCT01742637
- Testing
- Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%, Epiduo® Gel
- Volunteers
- 2,008 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Neural Tube Defects, Contraception
Efficacy and Safety Study for an Oral Contraceptive Containing Folate
The purpose of this study is to determine whether the study drug is safe and effective
- Conditions
- Neural Tube Defects, Contraception, Oral Contraceptives (OC)
- Trial name
- NCT00468481
- Testing
- Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
- Where
- 9 sites in United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Bayer
Gastrointestinal Neuroendocrine Pancreatic Tumor
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
- Trial name
- NCT06505395
- Testing
- SYHX2008 injection, Sandostatin LAR@
- Where
- China
- Volunteers
- 90 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Plasmodium Falciparum Infection
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To show the contribution of artefenomel (OZ439) to the clinical and parasiticidal effect of OZ439/Ferroquine (FQ) combination by analyzing exposure-response of OZ439 measured by Day 28 polymerase chain reaction…
- Trial name
- NCT03660839
- Testing
- Artefenomel (OZ439), Ferroquine (SSR97193)
- Where
- 7 sites in Benin, Burkina Faso and 3 more
- Volunteers
- 140 people
- Sponsor
- Sanofi
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
- Trial name
- NCT02971839
- Testing
- VX-561, IVA
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.